We are live on ! Find out more
CSTL icon

Castle Biosciences
CSTL

160 hedge funds and large institutions have $988M invested in Castle Biosciences in 2022 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 72 increasing their positions, 42 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,900% more call options, than puts

Call options by funds: $480K | Put options by funds: $8K

71% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 42

15% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 20

8% more capital invested

Capital invested by funds: $916M → $988M (+$72.2M)

4.96% more ownership

Funds ownership: 84.8% → 89.76% (+5%)

1% more funds holding

Funds holding: 159 → 160 (+1)

Holders
160
Holders Change
+1
Holders Change %
+0.63%
% of All Funds
2.52%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
23
Increased
72
Reduced
42
Closed
20
Calls
$480K
Puts
$8K
Net Calls
+$472K
Net Calls Change
+$381K

Top Buyers

Rank Fund Capital Flow
1
BG
Bellevue Group
Switzerland
+$25.1M
2
WA
Wasatch Advisors
Utah
+$13.5M
3
NCGI
Next Century Growth Investors
Minnesota
+$9.54M
4
IECM
Intrinsic Edge Capital Management
Illinois
+$8.78M
5
GPGA
Grandeur Peak Global Advisors
Utah
+$8.52M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$10.1M
2
Two Sigma Investments
Two Sigma Investments
New York
-$5.8M
3
Renaissance Technologies
Renaissance Technologies
New York
-$4.52M
4
NAMA
Nikko Asset Management Americas
New York
-$4.36M
5
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
-$4.36M
Name Holding Trade Value Shares
Change 		Change in
Stake
PFM
51
Premier Fund Managers
United Kingdom
$2.3M – – –
Swiss National Bank
52
Swiss National Bank
Switzerland
$2.15M +$149K +3,600 +8%
SLG
53
Stanley-Laman Group
Pennsylvania
$1.8M +$10K +242 +0.6%
IP
54
Isthmus Partners
Wisconsin
$1.8M +$99.8K +2,414 +6%
Envestnet Asset Management
55
Envestnet Asset Management
Illinois
$1.74M +$221K +5,337 +16%
Bank of America
56
Bank of America
North Carolina
$1.66M -$74K -1,791 -5%
BCI
57
Brinker Capital Investments
Pennsylvania
$1.58M +$312K +7,541 +27%
Swedbank
58
Swedbank
Sweden
$1.57M – – –
CSS
59
Cubist Systematic Strategies
Connecticut
$1.56M -$195K -4,708 -12%
PCM
60
Perkins Capital Management
Minnesota
$1.49M – – –
BA
61
Bridgewater Associates
Connecticut
$1.44M +$317K +7,679 +31%
AIMCA
62
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$1.31M +$1.21M +29,230 New
Morgan Stanley
63
Morgan Stanley
New York
$1.22M -$651K -15,757 -37%
California State Teachers Retirement System (CalSTRS)
64
California State Teachers Retirement System (CalSTRS)
California
$1.18M -$98.2K -2,377 -8%
RHJA
65
Rice Hall James & Associates
California
$1.17M +$38.8K +938 +4%
Renaissance Technologies
66
Renaissance Technologies
New York
$1.12M -$4.52M -109,281 -81%
AllianceBernstein
67
AllianceBernstein
Tennessee
$1.11M +$4.13K +100 +0.4%
JP Morgan Chase
68
JP Morgan Chase
New York
$1.09M +$31.2K +754 +3%
Two Sigma Advisers
69
Two Sigma Advisers
New York
$1.07M -$3.62M -87,700 -79%
KOCAA
70
Knights of Columbus Asset Advisors
Connecticut
$1.03M +$10.8K +261 +1%
RhumbLine Advisers
71
RhumbLine Advisers
Massachusetts
$984K +$42.9K +1,038 +5%
PA
72
Parallel Advisors
California
$964K +$5.79K +140 +0.6%
CP
73
Covenant Partners
Tennessee
$955K – – –
UCFA
74
United Capital Financial Advisors
Texas
$792K +$1.2K +29 +0.2%
ACM
75
Advisors Capital Management
New Jersey
$791K +$25.5K +617 +4%
1 2
3
4 5

CSTL Hedge Fund Activity: Q1 2022 in Review

160 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q1 2022, worth a combined $988M — up 7.9% from $916M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new CSTL positions and 20 closed out — a net gain of 3 holders — while 72 added to existing stakes and 42 trimmed.

The largest buyer was Bellevue Group, opening a new position worth an estimated $25.1M. The largest seller was Millennium Management, cutting an estimated $10.1M.

  • 160 institutional investors held Castle Biosciences (CSTL) as of Q1 2022, up from 159 in Q4 2021.
  • Funds reported $988M of Castle Biosciences stock for Q1 2022, up 7.9% quarter-over-quarter.
  • 23 funds opened new Castle Biosciences positions in Q1 2022 and 20 closed out, a net change of +3 holders.
  • The largest Castle Biosciences buyer in Q1 2022 was Bellevue Group, an estimated $25.1M added.
  • The largest Castle Biosciences seller in Q1 2022 was Millennium Management, an estimated $10.1M sold.

Based on aggregated 13F filings for Q1 2022.